Second hematopoietic stem cell transplantation (HSCT) may be an effective salvage therapy in some patients with acute myelogenous leukemia (AML) who relapse after an initial transplant. To investigate the availability of second HSCT, we reviewed our medical records of 10 recipients of second allogeneic transplants for leukemia recurring after initial autologous or allogeneic transplantation. Since year 2002, ten relapsed patients after first HSCT who received second HSCT from the available HLA-matched (N 5 7) or -mismatched (N 5 3) sibling or unrelated donors were retrospectively reviewed. The median patient age was 35 (range, 18$51) and there were 6 males and 4 females. The median follow-up duration after second transplant was 14 months (range, 4-59). The majority of patients had intermediate or unfavourable cytogenetic features. Seven patients were relapsed after autologous HSCT, as a first transplant. Others received from HLA-matched sibling donors. The main conditioning regimen for second transplant consisted in cyclophosphamide plus busulfan. For graft-versus-host-disease (GVHD) prophylaxis, we used combinations of cyclosporine A or tacrolimus in addition to short-term methotrexate. In all, 6 patients received peripheral blood stem cells. All transplanted patients were successfully engrafted. The overall incidence of acute and chronic GvHD was 60% and 43%, respectively. Two (20%) patients were relapsed so far. The estimated probability of disease-free survival rate at 4-year was 50%. The overall 5-year survival rate was 55%. When we considered the incidence of non-relapse transplant-related mortality (TRM), two recipients (20%) died due to one from severe acute GvHD and the other from fatal infectious cause. These results demonstrate that second HSCT for relapsed AML patients performed with appropriate clinical schedule is feasible, and is associated with a favourable outcome. We report the results of a prospective phase II study using a reduced intensity (RI) regimen and unrelated donor hematopoietic stem cell transplant (HCT) consisting of intravenous busulfan (Bu) 3.2 mg/kg daily for 2 doses, fludarabine 30 mg/m 2 daily for 5 doses, and ATG 15 mg/kg daily for 4 doses. GVHD prophylaxis was tacrolimus and methotrexate 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3 and 6. Twenty-one patients (median age 60, range 39-67) were treated; 19 were HLA matched with unrelated donors at A, B, C, DR, and DQ, and 2 pts had unrelated donors mismatched at one HLA class I allele, and 9 pts had one or more autologous HCTs prior to beginning the study. Follow up data is available on 20 pts. Grade II or higher regimen related toxicity (RRT) was reported in seventeen (85%) pts; gastrointestinal (n 5 14), mucositis (n 5 7), hepatic function (n 5 4), fever and infection (n 5 3), pulmonary function (n 5 2), and renal function (n 5 1). Veno-occlusive disease did not manifest in any pts. Six pts did not receive the full dosage of ATG because of ATG toxicities, including fever and chills, hypotension, capillary leak syndrome, and elevated bilirubin levels. The median day of engraftment was 15 days and 19 (95%) of twenty pts achieved 100% donor chimerism by day 80. Three pts subsequently lost donor chimerism and one never achieved higher than 90% donor chimerism; all 4 pts relapsed. Thirteen pts (65%) developed grade II or higher overall acute GHVD and chronic GVHD developed in five pts. Treatment related mortality (TRM) was 15% (95% confidence interval [CI], 5%-40%) at 3 months, and 35% (95% CI, 17%-63%) at 12 months. The most common cause of TRM was GVHD and infection. Actuarial overall survival at 3 years was 52% (95% CI, 27%-71%). All six pts who received reduced ATG dosages developed acute GVHD and one had relapse of disease, while of the remaining fourteen pts who received full ATG dosages 7 developed acute GVHD and 5 had relapse of disease. In conclusion, once daily Bu and fludarabine and unrelated donor HCT demonstrated good long term survival and disease control, however, TRM still exists with this regimen in this heavily treated, older pt population. Future use of a co-morbidity scoring tool may help select pts more suitable for this regimen. ATG significantly contributed to RRT, while GVHD and its treatment and complications primarily resulted in the TRM. Removing ATG and using other measures for GVHD prophylaxis and treatment may improve this RI regimen.
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SAFETY AND TOXICITY OF REDUCED INTENSITY ALLOGENEIC TRANS-PLANTATION WITH FLUDARABINE/MELPHALAN IN PATIENTS WITH AD-VANCED HAEMATOLOGICAL DISEASES. A SINGLE CENTRE EXPERIENCE
Khoo, L., Johnston, A.-M., Larsen, S., Joshua, D., Gibson, J. Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Aim: The safety and toxicity outcomes in a group of patients with advanced haematological diseases undergoing reduced intensity allogeneic stem cell transplantation using Fludarabine (30 mg/m 2 ) and Melphalan (140 mg/m 2 ) conditioning was examined. The majority (62%) of these heavily pre-treated patients had failed previous transplantation (22 autologous, and 1 allogeneic). Method: Thirty-seven patients underwent Sibling (Full Match) -19; Mismatch Sibling/Other Family -4, Matched Unrelated Donor -13 or Umbilical Cord Blood -1 transplantation. The median patient age was 50 years (range, 29 -64 years). Disease at time of transplant was: 6 primary acute leukaemia, 3 secondary acute leukaemia, 3 secondary MDS, 1 primary MDS, 11 multiple myeloma, 12 NHL and 1 myelofibrosis. Results: The median follow-up period was 21 months (range, 0.2 -84 months. Median survival was 9 months (range 0.2 -68 months) with 32% (12 patients) remaining alive at time of analysis. Sustained donor engraftment (neutrophils) occurred in 33 (89%) patients. The median time to neutrophil engraftment was 14 days (range 9-27); and for platelet engraftment 19 days (range 13-67). The median length of stay in hospital was 28 days (range 15-71). Twenty eight out of 37 patients (76%) were discharged from hospital post transplant. Nine patients (24%) required an Intensive Care admission. Seventeen out of the 37 patients (46%) had severe mucositis requiring opiates, with 6 requiring total parental nutrition. Graft vs Host Disease (GVHD) occurred in 24 individuals; 42% had acute GVHD (50% had .5 Grade 3 severity) and 55% had chronic GVHD (44% moderate to severe). The day 100 transplant-related mortality (TRM) was 32%, with the overall (all cause) mortality at 1 year of 51%. GVHD accounted for 6 (24%) deaths, primary disease 7 (28%) and sepsis 12 (48%). Conclusion: The combination of Fludarabine/Melphalan as a reduced intensity conditioning regime in this group of patients with advanced haematological malignancies can lead to prolonged disease control in up to one third of patients. However, it is not without its short term and long term toxicity, and is associated with a high day 100 transplant related mortality.
ALLOGENEIC TRANSPLANTATION IN RAPID SUCCESSION FROM TWO DONORS: IMMUNOLOGIC LESSON FOR STEM CELL ENGRAFTMENT
Zuckerman, T., Haddad, N., Katz, T., Gidoni, O., Faibish, T., Rowe, J.M. Rambam Medical Center, Haifa, Israel.
A 40-year old female was diagnosed with stage II Hodgkin disease in 1998. She was treated with standard therapy, relapsed and underwent autologous stem cell transplantation (SCT). Two years later she developed primary CNS B cell diffuse large cell lymphoma, was treated, relapsed systemically and underwent a second autologus SCT. Two years later she relapsed again and received various therapies with partial response. In February 2006 she underwent matched unrelated donor (MUD) SCT with reduced intensity protocol containing fludarabine 200 mg/m 2 and melphalan 140 mg/m 2 . GVHD prophylaxis consisted of cyclosporine and a short course of methotrexate. Donor (female) peripheral blood cells (7.7 Â 10 6 CD34/kg) were collected in advance and cryopreserved. The cells were transferred to a smaller freezing tank 24 hours before the transplant. At the initiation of the transplant procedure the cells were found to be completely thawed due to leaking tank. The cells were infused and an aliquot was shown to have a viability of only 20%. The donor registry was contacted but the donor refused a further donation at that time.
Hence, a second fully matched male donor was immediately located and a BM (1.74 Â 10 6 CD34 cells/kg) was given, remarkably, 5 days following the first stem cell infusion. No additional chemotherapy or immunosuppression was given. Fourteen days following the 2 nd stem cell transplantation the patient developed diffuse erythematous rash, fever and watery diarrhea. Chimerism analysis (PCR for STR) revealed presence of both donors and no evidence of patient cells in peripheral blood (Table 1) . I.V. solumedrol (2 mg/kg) was started to treat a possible acute GVHD. Repeat analysis is described in [ Table 1 ]. Unfortunately the patient remained neutropenic with no evidence for neutrophil and megakaryocyte precursors in BM. On day 42 from 1 st transplant the patient received CD34 positive stem cells boost (4.4 Â 10 6 cells/kg) from the same first female donor, engrafted promptly after 7 days and became transfusion independent. GVHD was not aggravated following stem cell boost. The patient gradually stopped steroids and cyclosporine and remains alive and well after all immunosuppressive therapy.
In conclusion, it appears that: (a) Low number of viable and thawed stem cells can survive and lead to engraftment. (b) Double allogeneic transplant ultimately leads to selection of a single donor as described for double cord-blood transplants.
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SE-VERE APLASTIC ANEMIA (SAA) USING A NON-MYELOABLATIVE CONDI-TIONING REGIMEN (NMCR)
Rosenthal, J., Pawlowska, A., Bolotin, E., Falk, P., Oliver, C., Forman, S. City of Hope National Medical Center, Duarte, CA.
Allogeneic bone marrow transplantation (ALLO BMT) is a curative treatment for patients (pts) with acquired SAA. Current preparative therapies are associated with early and late sequelae such as organ injury, and secondary malignancies. We report the use of NMCR in patients with SAA.
Patients and Methods: Four pts, ages 6-12 years, with SAA, had ALLO BMT from an HLA-identical sibling (SIB) (n 5 2) or a matched unrelated donor (MUD) (n 5 2). The reasons to offer NMCR were: delay in results of chromosome fragility studies, abnormal pulmonary function, history of recent life threatening infection, and failure to respond to immunosuppressive therapy. The NMCR consisted of fludarabine (FLU) (30 mg/m 2 Â 4), low dose cyclophosphamide (LDC) (5 mg/kg Â 4) and rabbit antithymocyte globulin (rATG) (1.5 mg/kg Â 4) in patients with SIB donor and FLU, LDC, at 15 mg/kg Â 4, rATG and a single fraction of total body irradiation at 200 cGy in patients with a MUD donor. Results: The NMCR was well tolerated in all 4 patients. Two pts who had a SIB BMT had no transplant-related toxicities, including mucositis or alopecia. Toxicities in the MUD BMT pts included mild mucositis and partial alpecia in both pts. One pt (Pt#3) had reactivation od Enterobacter cloacae sepsis with typhlitis and later CMV viremia. Myeloid and platelet engraftment were uneventful in 3 pts. The recovery of peripheral blood counts was slow in Pt #3 following typhlitis and CMV viremia. Myeloid engraftment occurred on day 119 (range 15-33 days). The median time to a platelet count .20,000 unsupported by transfusion was day 133, (range 12-76 days). Periodic engraftmen anlyses using short tandem repeat (STR) by PCR continue to show full donor chimerism in all 4 pts. Acute GvHD of the skin was recorded only in the 2 pts with MUD BMT. One patient had limited chronic GvHD (Pt#3). Three pts. continue to do well with a fully recovered hematopoietic system at 44, 19 and 5 months post transplant, respectively. Pt #3 had a slow recovery of her peripheral counts but is transfusion independent for greater than 2 months and doing well 7 months post-transplant. Conclusion: This data suggests that a non-myeloablative, immunosuppressive regimen is sufficient to provide a stable engraftment in the patients with SAA. This approach may be associated with decreased transplant-related, short-and long-term, toxicities. A larger study is needed to fully evaluate the outcome and the toxicity associated with this conditioning. Poster Session II
